<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31332" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Werdnig-Hoffmann Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Emmady</surname>
            <given-names>Prabhu D.</given-names>
          </name>
          <aff>UNC school of Medicine, Atrium Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bodle</surname>
            <given-names>Jeffrey</given-names>
          </name>
          <aff>Atrium Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhu Emmady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Bodle declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31332.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Werdnig-Hoffmann disease is a type of spinal muscular atrophy (SMA). It is the most common type of SMA and accounts for about 80% of individuals with this condition. This is the most severe form of spinal muscular atrophy, and infants with this condition experience severe muscle weakness with onset before 6 months of age, and presenting symptoms include severe motor weakness, poor muscle tone, and lack of motor development. This activity reviews the evaluation and management of Werdnig-Hoffmann disease and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of Werdnig-Hoffmann disease.</p></list-item><list-item><p>Review the appropriate evaluation of Werdnig-Hoffmann disease.</p></list-item><list-item><p>Outline the management options available for Werdnig-Hoffmann disease.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance Werdnig-Hoffmann disease and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31332">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31332.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Werdnig-Hoffmann disease is a type of spinal muscular atrophy (SMA), a rare form of motor neuron disease. It is the most common type of SMA and accounts for about 80% of individuals with this condition. There are 4 types of SMA. Werdnig-Hoffmann disease, also known as SMA1, is the most severe form. Infants with this condition experience severe muscle weakness with onset before 6 months of age and presenting symptoms include severe motor weakness, poor muscle tone, and lack of motor development.</p>
        <p>Motor neuron disease is a condition that affects the anterior horn cells of the motor neurons.<xref ref-type="bibr" rid="article-31332.r1">[1]</xref> These are the neurons that control voluntary muscle control. These are rare conditions that are often very severe, and no cure is available. Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), SMA, progressive bulbar palsy (PBP), primary lateral sclerosis (PLS), etc., These conditions spare sensory nerves, and individuals do not have sensory involvement. Individuals often have a combination of upper and lower motor neuron symptoms.</p>
        <p>SMA is a type of motor neuron disease. SMA presents&#x000a0;four subtypes.<xref ref-type="bibr" rid="article-31332.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Werdnig-Hoffmann disease, also known as acute spinal muscular atrophy, is SMA 1.</p>
          </list-item>
          <list-item>
            <p>SMA2, also known as intermediate SMA and chronic infantile SMA, has less severe symptoms than SMA1 and can sit without support but cannot stand or walk. SMA2 symptom onset is in infanthood.</p>
          </list-item>
          <list-item>
            <p>SMA3, also known as Kugelberg-Welander disease, presents after the age of 1, and the child is able to walk initially but later has the regression of motor abilities. They often develop poor balance, falls, and scoliosis.</p>
          </list-item>
          <list-item>
            <p>Individuals with SMA4 have minimal symptoms compared to the other forms, and symptom onset is after the age of 10 years. They usually have a normal lifespan. They usually have normal motor milestones and mobility.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31332.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Werdnig-Hoffmann disease is acquired in an autosomal recessive fashion.&#x000a0;Abnormality is noted in the&#x000a0;survival motor neuron (SMN) gene.&#x000a0;2 SMN genes have been identified. Both these genes are located on chromosome 5. SMN1 gene is located at&#x000a0;locus 5q11-q13. SMN2 is located next to the SMN1 gene. SMN1 is believed to cause SMA, while SMN2 is believed to affect the severity of the disease; higher SMN2 copies result in a milder form of SMA. In addition,&#x000a0;other genetic mutations have been identified to play a role in the severity of SMA. 1, and such identified mutation is the deletion of neuronal apoptosis inhibitory protein (NAIP) gene.<xref ref-type="bibr" rid="article-31332.r3">[3]</xref><xref ref-type="bibr" rid="article-31332.r4">[4]</xref></p>
      </sec>
      <sec id="article-31332.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Werdnig-Hoffmann disease affects about one in every 10,000 live births.<xref ref-type="bibr" rid="article-31332.r5">[5]</xref> It is the second most common autosomal recessive disorder. It can affect men and women equally.&#x000a0;About&#x000a0;50% of&#x000a0;individuals&#x000a0;die before birth. Age at presentation&#x000a0;is always prior to 6 months of age.</p>
      </sec>
      <sec id="article-31332.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Werdnig-Hoffmann disease&#x000a0;is a motor neuron disease in which there is anterior horn cell degeneration of the spinal cord. In utero, there is an excess of motor neuroblasts, with only half surviving until birth. After birth, the disease progresses with continued loss of motor neurons in the spinal cord and brainstem.<xref ref-type="bibr" rid="article-31332.r2">[2]</xref></p>
      </sec>
      <sec id="article-31332.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The majority of infants present at birth with severe weakness and wasting of the limbs. These infants have difficulty with swallowing and respiratory muscles. Other brain stem muscles also become involved, including the bulbar muscles. The distinctive feature of Werdnig-Hoffmann disease is that these individuals do not have any evidence of cerebral or higher central nervous system dysfunction. They have normal intelligence and demonstrate a keen sense of learning. Hypotonia is a very profound and classical finding.&#x000a0;Deep tendon reflexes are absent diffusely. Hypermobility of the joints is noted secondary to poor muscle tone. The twitching of muscles of the tongue (fasciculations) is noted. Tongue fasciculations are classical findings seen in motor neuron diseases and are also seen in other motor neuron diseases like amyotrophic lateral sclerosis, etc. The child does not gain head control and is unable to sit, stand, or walk. They often have difficulties with swallowing and breathing. They have a poor sucking reflex. They have a high risk of&#x000a0;aspiration pneumonia due to weak bulbar muscles. For infants in whom the symptoms develop after birth, motor regression&#x000a0;occurs, and there appears to be greater involvement of lower extremities than upper extremities. Muscles controlling extraocular movements are generally spared.<xref ref-type="bibr" rid="article-31332.r6">[6]</xref><xref ref-type="bibr" rid="article-31332.r7">[7]</xref></p>
      </sec>
      <sec id="article-31332.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of Werdnig-Hoffmann disease is made after a detailed clinical history and physical exam. A family history of the disease is highly suggestive of the disorder. Genetic tests are available prenatally and postnatally for a definitive diagnosis. Prenatally, chorionic villus sampling or amniocentesis can be done to obtain tissues for genetic testing.<xref ref-type="bibr" rid="article-31332.r8">[8]</xref><xref ref-type="bibr" rid="article-31332.r9">[9]</xref></p>
        <p>Molecular genetic testing is available and tests for the SMN gene. Werdnig-Hoffmann disease is caused by partial or complete loss of SMN gene. Electromyography (EMG) testing can be helpful in identifying myopathic potentials, but due to the widespread availability of genetic testing, it is no longer used in the diagnosis of this condition.</p>
      </sec>
      <sec id="article-31332.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no cure for Werdnig-Hoffmann disease.</p>
        <p>Nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide, and FDA approved for the treatment of SMA in adult and pediatric patients. It is administered intrathecally. It increases exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) and assists in the production of full-length SMN protein.<xref ref-type="bibr" rid="article-31332.r10">[10]</xref></p>
        <p>The treatment is supportive. Medications that are often used to improve symptoms include phenylbutyrate, valproic acid, albuterol, and hydroxyurea. Unfortunately, clinical trials have not shown any definite evidence that these medications prevent the progression of the disease. Treatment is directed towards symptom control. Symptomatic treatment is aimed at support with feeding, breathing, and motor weakness.<xref ref-type="bibr" rid="article-31332.r7">[7]</xref></p>
        <p>Feeding difficulties: Children often have difficulty with feeding and can have nutritional deficiencies or aspiration pneumonia secondary to swallowing difficulty. Percutaneous endoscopic gastrostomy (PEG) tubes can help with nutritional supplementation.</p>
        <p>Respiratory difficulties: Children may require non-invasive ventilator support initially as respiratory muscles are involved. As symptoms worsen, they may need tracheostomy and ventilator support.</p>
        <p>Motor weakness: Physical and occupational therapy can help with muscle stretching, strengthening, and minimizing contractures. Surgical procedures to help with scoliosis and braces may be helpful.</p>
      </sec>
      <sec id="article-31332.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Prader-Willi syndrome: Hypotonia, short stature, mental retardation, developmental delay, cognitive delay,&#x000a0;hypersomnia,&#x000a0;multiple endocrine abnormalities,&#x000a0;hypogonadism,&#x000a0;temperature instability, and&#x000a0;central adrenal insufficiency.<xref ref-type="bibr" rid="article-31332.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital myasthenia gravis:&#x000a0;caused by a mutation in an AChR subunit gene.&#x000a0;It presents with fatigable weakness involving the ocular and cranial muscles.<xref ref-type="bibr" rid="article-31332.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital myopathies: Slowly progressive muscle disease presenting with muscle weakness with hypotonia.<xref ref-type="bibr" rid="article-31332.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infantile Pompe disease: Muscle disease presenting with hypotonia, hearing problems, failure to thrive, and cardiac muscle involvement.<xref ref-type="bibr" rid="article-31332.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital muscular dystrophy (CMD): Individuals present with hypotonia, contractures, delay of motor milestones.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Arthrogryposis multiplex congenita: Individuals develop multiple joint contractures.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Adrenoleukodystrophy: Individuals present with seizures, trouble swallowing, hearing loss, and cognitive impairment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31332.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for Werdnig Hoffmann disease is very poor. The disease presents before 6 months of age, and it is a progressive muscular disorder that often results in early death.&#x000a0;Most patients die prematurely either in infancy or early childhood, often by 2 years of life. This is the&#x000a0;most common genetic cause of infant mortality.<xref ref-type="bibr" rid="article-31332.r7">[7]</xref></p>
      </sec>
      <sec id="article-31332.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Orthopedic complications are&#x000a0;common&#x000a0;secondary to hypotonia, muscle weakness, and wasting. Scoliosis, joint contractures, ankylosis&#x000a0;are seen often. Physical and occupational therapy, orthopedic surgery, and braces can help with the management of these symptoms.</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonia may occur secondary to bulbar weakness.</p>
          </list-item>
          <list-item>
            <p>Malnutrition is a common complication secondary to swallowing difficulty.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31332.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The diagnosis of Werdnig-Hoffmann disease can be stressful and overwhelming for the families. Patient education must be an important part of the clinical management of patients with this condition. Counseling must be given about prognosis, complications, and outcomes. Support groups can help with the management of issues like anxiety, frustration, loneliness, and depression. The patient&#x02019;s families should be counseled about the diagnosis and the prognosis. Clinicians and family members should also establish medical and psychosocial treatment plans.</p>
      </sec>
      <sec id="article-31332.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Werdnig-Hoffmann disease is a rare condition and presents with severe symptoms in an infant. An interprofessional approach is recommended when managing patients with this condition. The presentation of this disease is complex, and a need for prompt diagnosis and initiation of treatment is imperative. This is best achieved by care coordination and interprofessional communication between pediatricians, pediatric neurologists, nurses, pharmacists, physical and occupational therapists. This can help also reduce hospitalization and decrease emergency department visits. Caring for patients with Werdnig-Hoffmann disease is complex and requires extensive interprofessional communication to improve patient outcomes.</p>
      </sec>
      <sec id="article-31332.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31332">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/werdnig-hoffmann-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31332">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31332/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31332">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31332.s15">
        <title>References</title>
        <ref id="article-31332.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDermott</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of motor neurone disease.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Mar</month>
            <day>22</day>
            <volume>336</volume>
            <issue>7645</issue>
            <fpage>658</fpage>
            <page-range>658-62</page-range>
            <pub-id pub-id-type="pmid">18356234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shababi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lorson</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?</article-title>
            <source>J Anat</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>224</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-28</page-range>
            <pub-id pub-id-type="pmid">23876144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The Genetics of Spinal Muscular Atrophy: Progress and Challenges.</article-title>
            <source>Neurotherapeutics</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>290</fpage>
            <page-range>290-302</page-range>
            <pub-id pub-id-type="pmid">25413156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sedghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behnam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fazel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salehi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meamar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hosseinzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Genotype-phenotype correlation of survival motor neuron and neuronal apoptosis inhibitory protein genes in spinal muscular atrophy patients from Iran.</article-title>
            <source>Adv Biomed Res</source>
            <year>2014</year>
            <volume>3</volume>
            <fpage>74</fpage>
            <pub-id pub-id-type="pmid">24627882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhaart</surname>
                <given-names>IEC</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Aartsma-Rus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Lochm&#x000fc;ller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2017</year>
            <month>Jul</month>
            <day>04</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>124</fpage>
            <pub-id pub-id-type="pmid">28676062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tiziano</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2011</year>
            <month>Nov</month>
            <day>02</day>
            <volume>6</volume>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">22047105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Spinal Muscular Atrophy.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>831</fpage>
            <page-range>831-46</page-range>
            <pub-id pub-id-type="pmid">26515624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khaniani</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Derakhshan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abasalizadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prenatal diagnosis of spinal muscular atrophy: clinical experience and molecular genetics of SMN gene analysis in 36 cases.</article-title>
            <source>J Prenat Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>32</fpage>
            <page-range>32-4</page-range>
            <pub-id pub-id-type="pmid">24175014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harding</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Kariya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monani</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yum</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tennekoon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Finkel</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Spectrum of neuropathophysiology in spinal muscular atrophy type I.</article-title>
            <source>J Neuropathol Exp Neurol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-24</page-range>
            <pub-id pub-id-type="pmid">25470343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neil</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Bisaccia</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-203</page-range>
            <pub-id pub-id-type="pmid">31093018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angulo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Cataletto</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>1249</fpage>
            <page-range>1249-63</page-range>
            <pub-id pub-id-type="pmid">26062517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engel</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Selcen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sine</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.</article-title>
            <source>Lancet Neurol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>420</fpage>
            <page-range>420-34</page-range>
            <pub-id pub-id-type="pmid">25792100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassandrini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trovato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubegni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lenzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fiorillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baldacci</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Minetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Astrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santorelli</surname>
                <given-names>FM</given-names>
              </name>
              <collab>Italian Network on Congenital Myopathies</collab>
            </person-group>
            <article-title>Congenital myopathies: clinical phenotypes and new diagnostic tools.</article-title>
            <source>Ital J Pediatr</source>
            <year>2017</year>
            <month>Nov</month>
            <day>15</day>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <pub-id pub-id-type="pmid">29141652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31332.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishnani</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Bali</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kravitz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Millington</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Nicolino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Slonim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Tifft</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pompe disease diagnosis and management guideline.</article-title>
            <source>Genet Med</source>
            <year>2006</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>267</fpage>
            <page-range>267-88</page-range>
            <pub-id pub-id-type="pmid">16702877</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
